Popular Pre-Market Trades in US Stocks
BUUU, up 21.16% in pre-market, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation.
Nebius is up 9.72% in pre-market. Based on recent key news:
<ol>
<li>
On March 11, NVIDIA announced plans to invest $2 billion in Nebius, driving its pre-market stock price up 9%. This investment plan is seen as a strong vote of confidence in Nebius's future growth potential, further enhancing market expectations for its AI infrastructure business.
</li>
<li>
On March 10, Nebius announced the expansion of its business in the Asia-Pacific region to support the growing global demand for AI infrastructure. The company appointed John Haarer as General Manager for Asia-Pacific and Japan, responsible for business expansion in Singapore, Japan, South Korea, and India, demonstrating the company's proactive positioning in the global market.
</li>
<li>
On March 9, Nebius appointed Dan Lawrence as Senior Vice President and General Manager for the Americas, responsible for expanding the North American market. This move reflects the company's emphasis on the North American market and plans to meet the growing demand for AI infrastructure through enhanced market strategies. The demand for AI infrastructure is growing strongly, attracting market attention.
</li>
</ol>
Top Gainers in Pre-Market US Stocks
Kala Pharmaceuticals is up 64.24% in pre-market. Based on recent key news:
<ol>
<li>
On March 11, Kala Bio announced that its Researgency.ai platform is now live and plans to launch its first commercial AI product in about 14 days. The platform is positioned to exceed $180 billion in the AI healthcare market by 2030, driving a significant increase in stock price. Source: GlobeNewswire
</li>
<li>
On March 11, Kala Bio stated that the enterprise consulting volume for its AI platform has increased by 1,445% from Q1 2024 to Q2 2025. This data indicates a surge in market demand for multi-agent AI systems, further boosting investor confidence. Source: GlobeNewswire
</li>
<li>
On March 11, the Researgency.ai platform is undergoing a rebranding and plans to launch its first AI agent specifically designed for biotechnology within two weeks. This innovative development showcases the company's technological leadership in the biotechnology industry, attracting market attention. Source: GlobeNewswire The AI healthcare market is growing rapidly, capturing investor interest.
</li>
</ol>
GEE is up 46.02% in pre-market. Based on recent key news:
<ol>
<li>
On March 11, GEE Group hired Roth Capital Partners to assist in evaluating strategic options, including received expressions of unsolicited interest. This move has driven the stock price up, as the market anticipates potential acquisitions or strategic partnerships
</li>
<li>
On March 10, board member Bill Isaac retired and resigned from his director position. Although this event has limited impact on the stock price, it may raise concerns about the company's governance structure.
</li>
<li>
On March 11, GEE Group announced that it would formally respond to interested parties privately, further driving up the stock price as investors anticipate potential strategic adjustments. The market has strong expectations for strategic adjustments, with noticeable capital inflow.
</li>
</ol>
Domo-B pre-market rose 39.50%. Based on recent key news:
<ol>
<li>
On March 10, Domo announced its fourth-quarter financial report, with an EPS of $0.03, exceeding expectations and driving up the stock price. The financial report showed revenue growth, with subscription revenue increasing by 2% year-on-year and billing growth of 8%. Source: Benzinga
</li>
<li>
On March 11, Domo emphasized the importance of its AI platform strategy, with a significant increase in customer adoption rates, boosting market confidence. The company expects short-term revenue to remain flat but is focused on profitability and innovation. Source: Business Wire
</li>
<li>
On March 11, analysts gave Domo a &#34;Buy&#34; rating with a target price of $11.50, which is 169.3% higher than the current stock price, enhancing investor confidence. Source: Reuters The data analysis industry has recently performed strongly, with AI applications driving growth
</li>
</ol>

BUUU

NBIS

BUUU pre-market up 21.16%; Nebius pre-market up 9.72%; Kala Pharmaceuticals pre-market up 64.24%; GEE pre-market up 46.02%; Domo-B pre-market up 39.50%

Popular pre-market trades in the US stock market: BUUU pre-market up 21.16%; Nebius pre-market up 9.72%